Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome

Am J Hematol. 2009 May;84(5):314-5. doi: 10.1002/ajh.21387.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Anemia, Aplastic / complications
  • Cancer Vaccines*
  • Clinical Trials, Phase I as Topic
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Injections, Subcutaneous
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / immunology
  • Leukemia, Myeloid, Acute / physiopathology
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / etiology
  • Myelodysplastic Syndromes / immunology
  • Oligopeptides / administration & dosage*
  • Oligopeptides / adverse effects
  • Peptides / administration & dosage*
  • Peptides / adverse effects
  • Recurrence
  • Remission Induction
  • Vaccination
  • WT1 Proteins / administration & dosage
  • WT1 Proteins / adverse effects
  • WT1 Proteins / chemistry
  • WT1 Proteins / genetics
  • WT1 Proteins / therapeutic use*

Substances

  • CMTWNQMNL peptide
  • Cancer Vaccines
  • Oligopeptides
  • Peptides
  • WT1 Proteins